ArticleAnnals of the rheumatic diseases2014
Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.
Article in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04474392 (Sputum Studies of Anti-Citrullinated Protein Antibodies), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Mortality in patients with psoriatic arthritis: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.Arthritis care & research · 2023Pooled it
- Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Trial
- Effect of intermittent aerobic exercise on sleep quality and sleep disturbances in patients with rheumatoid arthritis - design of a randomized controlled trial.BMC musculoskeletal disorders · 2014Trial
- All-cause 2-year mortality after hospital discharge among 4273 adults in Nairobi, Kenya with a special focus on inflammatory rheumatic diseases.Journal of global health · 2025Article
- Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.RMD open · 2023Article
- Excess psoriasis and psoriatic arthritis mortality during the COVID-19 pandemic in the United States: A nationwide population-based study from 2010 to 2021.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Article
- Early intervention in psoriasis: Where do we go from here?Frontiers in medicine · 2022Review
- All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019.RMD open · 2021Article
- Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis.Mediators of inflammation · 2021Article
- Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia.Psoriasis (Auckland, N.Z.) · 2021Article
- Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford, England) · 2019Article
- The Risk of Mortality among Psoriatic Patients with Varying Severity: A Nationwide Population-Based Cohort Study in Taiwan.International journal of environmental research and public health · 2018Article
- Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study.The Journal of investigative dermatology · 2018Article
- Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study.The Journal of investigative dermatology · 2018Article
- Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study.BMC rheumatology · 2018Article
- Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.Cost effectiveness and resource allocation : C/E · 2018Article
- Classification and Outcome Measures for Psoriatic Arthritis.Frontiers in medicine · 2018Review
- Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study.RMD open · 2018Article
- Pediatric Psoriasis Comorbidity Screening Guidelines.JAMA dermatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThere are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA).
methodsA longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death.
resultsPatients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=82 258) were identified; 1 442 357 person-years were observed during which 21 825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95).
conclusionsPatients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.